Literature DB >> 7855615

Multiple drug resistance: biologic basis and clinical significance in renal-cell carcinoma.

A E Chapman1, L J Goldstein.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7855615

Source DB:  PubMed          Journal:  Semin Oncol        ISSN: 0093-7754            Impact factor:   4.929


× No keyword cloud information.
  5 in total

1.  99mTc-MIBI scintigraphy in metastatic renal cell carcinoma: clinical validation of the relationship between 99mTc-MIBI uptake and P-glycoprotein expression in tumour tissue.

Authors:  E Derebek; Z Kirkali; A S Dogan; B Degirmenci; M Yilmaz; E Igci; K Yorukoglu; I Kovanlikaya; H Durak
Journal:  Eur J Nucl Med       Date:  1996-08

2.  A phase II trial of pemetrexed in patients with metastatic renal cancer.

Authors:  R Thödtmann; T Sauter; S Weinknecht; L Weissbach; J Blatter; U Ohnmacht; A- R Hanauske
Journal:  Invest New Drugs       Date:  2003-08       Impact factor: 3.850

3.  Phase IB study of doxorubicin in combination with the multidrug resistance reversing agent S9788 in advanced colorectal and renal cell cancer.

Authors:  C J Punt; E E Voest; E Tueni; A T Van Oosterom; A Backx; P H De Mulder; B Hecquet; C Lucas; B Gerard; H Bleiberg
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

4.  Cytochrome P450 CYP3A in human renal cell cancer.

Authors:  G I Murray; M C McFadyen; R T Mitchell; Y L Cheung; A C Kerr; W T Melvin
Journal:  Br J Cancer       Date:  1999-04       Impact factor: 7.640

5.  Cytochrome P450 CYP1B1 activity in renal cell carcinoma.

Authors:  M C E McFadyen; W T Melvin; G I Murray
Journal:  Br J Cancer       Date:  2004-08-31       Impact factor: 7.640

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.